Skip to main content
S&P 5007,663.01+0.94%DOW52,640.18+1.11%NASDAQ26,349.14+1.03%BTC$77,335.00+0.49%ETH$2,499.33+3.09%GOLD$4,432.70+0.58%OIL$98.71-3.68%
Smart Investors Daily
CG

NASDAQ · CGTX

Cognition Therapeutics, Inc.

Healthcare · Biotechnology

$0.98

Up+$0.02 (+1.89%)

Updated Sep 11, 2026, 1:44 PM

SID Score

3.4/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
119.2M
P/E ratio
-3.13
Dividend yield
0.00%
52-week range
$0.55 – $1.76
Volume
300.39K
Avg. volume
1.86M

Price performance

CGTX price history

1M range · 20 trading sessions · Daily adjusted prices

CGTX closed at $0.98 after 20 trading sessions, down 5.80% for the selected period.

Last close
$0.98
Period change
-5.80%
Period low
$0.96
Period high
$1.06
Daily close
View OHLC price history
CGTX OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Sep 10, 2026$0.99$1.005$0.97$0.9797300.39K
Sep 9, 2026$1.01$1.03$0.9864$0.99473.92K
Sep 8, 2026$1.02$1.04$1.00$1.01261.51K
Sep 4, 2026$1.05$1.05$1.01$1.03377.47K
Sep 3, 2026$1.05$1.06$1.02$1.05261.51K
Sep 2, 2026$1.01$1.07$1.005$1.05378.4K
Sep 1, 2026$1.02$1.025$0.9815$1.01336.78K
Aug 31, 2026$1.02$1.05$1.01$1.03294.61K
Aug 28, 2026$1.07$1.07$1.02$1.02347.44K
Aug 27, 2026$1.07$1.08$1.04$1.06273.37K
Aug 26, 2026$1.03$1.06$0.9943$1.05466.21K
Aug 25, 2026$0.9803$1.035$0.9803$1.03416.43K
Aug 24, 2026$0.99$0.9999$0.96$0.9845249.74K
Aug 21, 2026$0.975$1.01$0.9699$0.9959308.33K
Aug 20, 2026$0.9845$0.9866$0.9301$0.9567303.45K
Aug 19, 2026$0.9942$1.02$0.961$0.9788805.64K
Aug 18, 2026$1.01$1.03$0.9816$0.9819379.83K
Aug 17, 2026$1.01$1.035$1.01$1.02434.83K
Aug 14, 2026$1.04$1.0498$0.9997$1.01509.46K
Aug 13, 2026$1.03$1.0583$1.03$1.04398.32K

Latest CGTX news

The latest Smart Investors Daily articles mentioning CGTX.

Stock researchCompany · Overview

CGTX research

Overview

Company profile and research snapshot.

Company profile

Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
—
Implied upside
—
Analysts
—
CGTX recent ratings
DateFirmRatingTarget
Mar 27, 2026Chardan CapitalBuy—
Dec 4, 2025HC Wainwright & Co.Buy—
Nov 21, 2025B. Riley SecuritiesBuy—
Nov 19, 2025HC Wainwright & Co.Buy—
Aug 8, 2025Chardan CapitalBuy—
Open full forecast

News briefing

Generated Sep 10, 2026, 9:14 PM

Why Is CGTX Down Today?

Cognition Therapeutics (CGTX) declined marginally by 1.04% today, with minimal trading pressure evident as the company prepares for investor outreach activities. The modest pullback appears driven by broader market dynamics rather than company-specific negative news, as CGTX announced its participation in an upcoming industry conference.

    Bottom line: CGTX's modest 1.04% decline appears disconnected from negative fundamentals, with the company positioning itself for potential positive exposure at the H.C. Wainwright conference. Investors should monitor the specifics of management's presentation for clinical progress, strategic partnerships, or financial developments that could meaningfully impact the investment thesis.

    Yahoo · Sep 8, 2026

    Cognition Therapeutics to Present at H.C. Wainwright Global Investment Conference

    PURCHASE, N.Y., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, announced that the Company’s president and CEO, Lisa Ricciardi intends to present at the H.C. Wainwright 28th Annual Global Investment Conference on Tuesday, September 15, 2026 at 2:30 p.m. Eastern Time. During her presentation, Ms. Ricciardi will discuss progress on the Company’s development of zervimesine for Alzheimer

    AI research layers

    Interpretive context generated from the platform’s current data sources.

    No results

    AI research layers have not been published yet.

    Featured By